Company Information

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE1083.60-9.4 (-0.86 %)
PREV CLOSE ( ) 1093.00
OPEN PRICE ( ) 1099.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 9938
TODAY'S LOW / HIGH ( )1081.45 1099.70
52 WK LOW / HIGH ( )581.5 1177
NSE1084.05-9.2 (-0.84 %)
PREV CLOSE( ) 1093.25
OPEN PRICE ( ) 1095.20
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1084.05 (99)
VOLUME 923839
TODAY'S LOW / HIGH( ) 1080.80 1097.00
52 WK LOW / HIGH ( )581.25 1177.1
Managing DirectorK Nithyananda Reddy
Company SecretaryB Adi Reddy
Promoter & Non-Executive DirectorPV Ramprasad Reddy
Independent DirectorDeepali Pant Joshi
Non Executive Independent DirectorSavita Mahajan
Girish Vanvari
Santanu Mukherjee
Satakarni Makkapati
Whole Time DirectorM Madan Mohan Reddy
Non Independent & Non Executive DirectorP Sarath Chandra Reddy
Incorporation Year : 26-12 1986

Registered Office :

Address : Plot No. 2,Maitrivihar ,Ameerpet Hyderabad,
Telangana-500038 .

Phone : 040-23736370 / 23747340

Email :  info@aurobindo.com 

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.